- Home
- AAT vs ARVN Comparison
AAT vs ARVN Comparison
Compare AAT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAT
- ARVN
- Stock Information
- Founded
- AAT 1967
- ARVN 2015
- Country
- AAT United States
- ARVN United States
- Employees
- AAT N/A
- ARVN N/A
- Industry
- AAT Real Estate Investment Trusts
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- AAT Real Estate
- ARVN Health Care
- Exchange
- AAT Nasdaq
- ARVN Nasdaq
- Market Cap
- AAT 1.6B
- ARVN 1.7B
- IPO Year
- AAT 2011
- ARVN 2018
- Fundamental
- Price
- AAT $27.87
- ARVN $25.11
- Analyst Decision
- AAT Hold
- ARVN Strong Buy
- Analyst Count
- AAT 2
- ARVN 13
- Target Price
- AAT $25.00
- ARVN $61.08
- AVG Volume (30 Days)
- AAT 206.7K
- ARVN 718.1K
- Earning Date
- AAT 10-29-2024
- ARVN 10-30-2024
- Dividend Yield
- AAT 4.78%
- ARVN N/A
- EPS Growth
- AAT 17.42
- ARVN N/A
- EPS
- AAT 0.97
- ARVN N/A
- Revenue
- AAT $452,499,000.00
- ARVN $161,100,000.00
- Revenue This Year
- AAT N/A
- ARVN $237.44
- Revenue Next Year
- AAT $5.98
- ARVN N/A
- P/E Ratio
- AAT $28.99
- ARVN N/A
- Revenue Growth
- AAT 5.13
- ARVN 1.07
- 52 Week Low
- AAT $18.44
- ARVN $21.17
- 52 Week High
- AAT $28.96
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- AAT 56.51
- ARVN 48.81
- Support Level
- AAT $26.81
- ARVN $21.17
- Resistance Level
- AAT $27.84
- ARVN $28.70
- Average True Range (ATR)
- AAT 0.62
- ARVN 1.72
- MACD
- AAT -0.01
- ARVN -0.41
- Stochastic Oscillator
- AAT 53.81
- ARVN 51.44
About AAT American Assets Trust Inc.
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.